MODERNA INC. DL-,0001 WKN: A2N9D9 ISIN: US60770K1079 Forum: Aktien Thema: Hauptdiskussion

Aber es läuft

Bin erst bei 120 eingestiegen

Alles mitnehmen was geht, Rest ist egal. Bin leider bei 100€ nicht eingestiegen total verpasst. 🙈 allen viel Glück 🍀

...raffiniert !!!

Bin short gegangen. Oft gibt es nach der Aufnahme in einen Index ein Set-Back in den Tagen nach dem Kauf-Zwang von Instrumenten, die den Index abbilden.

Danke. Leider hatte ich nur eine kleine Position

Das ist doch perfekt 👌 Glückwunsch 🎊🍾🎉

Die Rallye ist mir zu heiß. Deswegen habe ich meine Anteile abgestoßen. 700% Gewinn

October 7, 2026 1:44 PM Tempus AI Doubles Down On Moderna and Merck Cancer Vaccine Infrastructure by Vandana Singh Benzinga Staff Writer Tempus Inc. (NASDAQ:TEM) on Wednesday expanded its multi-year collaboration for intismeran autogene (V940/mRNA-4157) individualized neoantigen therapy (INT) combined with Keytruda (pembrolizumab) for completely resected stage IIB-IV melanoma and other cancer types. Intismeran autogene is jointly developed by Moderna Inc. (NASDAQ:MRNA) and Merck & Co. Inc. (NYSE:MRK). Expanded Precision Oncology Alliances The collaboration builds on joint efforts initiated last year and will support preparations for the potential commercialization of intismeran autogene. As part of the collaboration, Tempus will manage the timely collection and transfer of tumor tissue and blood samples required for next-generation sequencing (NGS). Subject to applicable regulatory approvals, Tempus will also provide NGS services to support the intismeran autogene design and manufacturing process. Financial terms of the collaboration were not disclosed. https://www.benzinga.com/news/health-care/26/10/62228412/tempus-ai-doubles-down-on-moderna-and-merck-cancer-vaccine-infrastructure?mod=mw_quote_news

https://www.tipranks.com/news/the-fly/moderna-price-target-raised-to-95-from-89-at-morgan-stanley-thefly-news?mod=mw_quote_news

Is Now the Time to Cash Out of the S&P 500's Top 3 Stocks of 2026? These stocks have all soared more than 350% this year. By David Jagielski, CPA – Oct 6, 2026 at 4:00PM EST Moderna Moderna is not a stock I would have guessed would have made this list, even if I had 400 guesses. Healthcare stocks can rally quickly on positive clinical trials and related developments, and that's certainly what's happened with Moderna. For much of the year, the stock was going nowhere. Then, in August, Moderna and Merck announced encouraging results from a trial involving a cancer vaccine they have been working on. When paired with Merck's Keytruda, it was a more effective treatment for melanoma patients than Keytruda alone. A rally was certainly justified, but with Moderna's stock soaring around 550% this year, I question whether investors have gotten carried away as they have in the past with this stock. The treatment hasn't obtained approval yet, and even if it does, it may not generate the massive growth needed to justify this type of rally. I'd sell the stock before it inevitably comes back down to reality. https://www.fool.com/investing/2026/10/06/is-now-the-time-to-cash-out-of-the-s-and-p-500-s-top-3-stocks-of-2026/?source=djc&utm_source=djc&utm_medium=feed&utm_campaign=article&referring_guid=edf75637-e3c0-42c4-8acb-32169c28bb19&mod=mw_quote_news

vielen Dank für die info für den Absturz von Heute

Warum heute alle so wortkarg?

Warum fällt es denn hier heute auch so steil nach unten?

https://www.investors.com/news/technology/biotech-stocks-moderna-vaxcyte-revolution-medicines-sell-off/?src=A00619&refcode=aflMarketWatch&mod=mw_quote_news

Bin jetzt mal in novavax rein da haben die Drecksamis schön verkauft.Vielleocht steigt diese Nullaktie aich mal.Hier komme ich auch wieder rein.